Martin F. Bachmann

from Wikipedia, the free encyclopedia
Martin Bachmann (2019)

Martin Fabian Bachmann (born December 15, 1967 in Winterthur ) is a Swiss immunologist.

Life

Martin Fabian Bachmann made a name for himself in the field of therapeutic vaccines and virus-like particles. He is Professor of Immunology at the University of Bern , the University of Oxford and Director of the International Immunology Institute of Anhui Agricultural University , Hefei , China . Martin Bachmann is the founder and co-founder of several biotech companies that are active in the field of therapeutic vaccines for humans (Saiba GmbH, HealVAX GmbH and DeepVax GmbH) and animals (Hypopet AG, Evax AG).

Martin Bachmann began his research career in the field of antiviral immune responses in the laboratory of Nobel Prize winner Rolf Zinkernagel (1991–1995) before working with Pam Ohashi in Toronto (1995–1997) and as a Principle Investigator at the Basel Institute for Immunology (1997–2000).

In a next step, Bachmann focused his research on vaccine development and headed research at Cytos Biotechnology AG in Schlieren , Canton of Zurich (2000–2012) for over 10 years . During this time, clinical proof of concept in humans was achieved in several indications, including a vaccine against high blood pressure, smoking, allergy and asthma. A vaccine he developed against Alzheimer's disease is in a registration study at Novartis . From 2012, Bachmann turned back to the academy and continued to focus on therapeutic vaccines based on virus-like particles. In cooperation with Evax AG and Hypopet AG , a successful proof-of-concept for therapeutic vaccines against insect bite allergy in horses and atopic dermatitis in dogs was obtained. It was also possible to make cats hypoallergenic by means of a vaccination in order to make it easier to coexist with allergic owners.

Scientific misconduct and insider trading (Cytos)

As a member of the executive board and head of research at Cytos Biotechnology AG, Bachmann published a study in 2002 just before the company went public. The study looked at a new way to make vaccinations against viruses more effective. He showed in a graphic how the tumor size of six vaccinated mice had decreased, but he omitted the two animals in which his substance was unsuccessful. The study was withdrawn; after an investigation, the University of Zurich came to the conclusion that there had been deception and scientific misconduct.

Bachmann was convicted of insider trading in 2016 because he sold or bought shares in Cytos earlier in 2009 thanks to insider information. He received a conditional fine of 84,000 francs and had to pay 55,903 francs for an unlawful financial advantage.

Awards

Bachmann received the silver medal in 1991 for his diploma thesis at the ETH Zurich on the subject of "On the influence of cell adhesion molecules on the adhesiveness of the extracellular matrix". His PhD thesis was also awarded the ETH silver medal in 1995.

In 1998 he received the Pfizer Prize for Immunology .

The Swiss Technology Award was given twice for work at Cytos (2004) and Hypopet (2013).

Web links

Commons : Martin F. Bachmann  - Collection of images, videos and audio files

Individual evidence

  1. ↑ Effect of immunization against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomized, placebo-controlled phase IIa study. March 8, 2008, accessed November 21, 2019 .
  2. ^ A Vaccine against Nicotine for Smoking Cessation: A Randomized Controlled Trial. June 25, 2008. Retrieved November 21, 2019 .
  3. ↑ Assessment of clinical efficacy of CYT003 ‐ QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study. June 14, 2011, accessed November 21, 2019 .
  4. ↑ The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma. February 4, 2013, accessed November 21, 2019 .
  5. ^ Treating insect-bite hypersensitivity in horses with active vaccination against IL-5. April 4, 2018, accessed November 21, 2019 .
  6. ^ Vaccination against IL-31 for the treatment of atopic dermatitis in dogs. April 4, 2018, accessed November 21, 2019 .
  7. ↑ Immunization of cats to induce neutralizing antibodies against Fel d 1, the major feline allergen in human subjects. May 2, 2019, accessed November 21, 2019 .
  8. ↑ a b A dubious Corona hero , Tages-Anzeiger, June 29, 2020, p. 3.
personal data
SURNAME Bachmann, Martin F.
ALTERNATIVE NAMES Bachmann, Martin Fabian (full name)
BRIEF DESCRIPTION Swiss immunologist
DATE OF BIRTH December 15, 1967
PLACE OF BIRTH Winterthur